生物制药公司SCYNEXIS宣布，其研发的静脉注射抗真菌药物Scy-247已启动一期临床研究，首批志愿者顺利完成单次递增剂量（SAD）与多次递增剂量（MAD）试验的首次给药。该试验旨在评估Scy-247在人体内的安全性、耐受性及药代动力学特征，为后续适应症开发奠定基础。
生物制药公司SCYNEXIS宣布，其研发的静脉注射抗真菌药物Scy-247已启动一期临床研究，首批志愿者顺利完成单次递增剂量（SAD）与多次递增剂量（MAD）试验的首次给药。该试验旨在评估Scy-247在人体内的安全性、耐受性及药代动力学特征，为后续适应症开发奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.